**Appendix Table E57. Results from studies assessing the ability of VASP to predict other clinical events in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Clinical Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., bleeding or no bleeding)** | **No. with outcome status within phenotype group** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Djukanovic, 2008{Djukanovic, 2008 163 /id}18719318SerbiaNR | clopidogrel 75 mg + Aspirin 100 mg | VASP phosphorylation | Revascularization | NR | 1 year | Bad responder | Revascularization | 0 | OR (calculate)=1 | NR | P=1.0(bad vs good responder)[Fisher’s exact test] | NR | NR | NR |
|  |  |  |  |  |  | Good responder |  | 0 | NR | NR | NR | NR | NR | NR |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Bonello, 2007{Bonello, 2007 199 /id}17488353FranceNR | clopidogrel LD 300-mg followed by 75 mg daily | VASP | ACS  | defined according to the ACC/AHA guidelines | 6-month | Quintile 1 | ACS | 0 | OR (calculate)=410 | 23.1-7306.8 | P<0.0001(Q1 vs Q2-5)[Fisher’s exact test] | NR | NR |  |
|  |  |  |  |  |  | Quintiles 2-4 |  | 18(15.6) |  |  |  |  |  |  |
|  | clopidogrel LD 300-mg followed by 75 mg daily | VASP | PCI | PCI | 6-month | Quintile 1 | PCI | 0 | OR (calculate)=410 | NR | P<0.0001(Q1 vs Q2-5)[Fisher’s exact test] | NR | NR |  |
|  |  |  |  |  |  | Quintiles 2-5 |  | 16(13.9) |  |  |  |  |  |  |
|  | clopidogrel LD 300-mg followed by 75 mg daily | VASP | Bypass surgery | Bypass surgery | 6-month | Quintile 1 | Bypass surgery | 0 | OR (calculate)=307 | NR | P<0.0001(Q1 vs Q2-5)[Fisher’s exact test] | NR | NR |  |
|  |  |  |  |  |  | Quintiles 2-5 |  | 2(1.7) |  |  |  |  |  |  |
| El Ghannudi, 2011{El, 2011 3 /id}21524751France NR | Clopidogrel + aspirin | VASP | Target lesion revascularization |  | 9 months  | non-diabetic responders (NDM-R) (PRI <61%) |  | 9 (9.5%) | OR (calculate)=22 | NR | P=0.04(nonresponders vs responder)[Fisher’s exact test] |  |  |  |
|  |  |  |  |  |  | non-diabetic low responders (NDM-LR) (PRI≥61%) |  | 17 (9.7%) |  |  |  |  |  |  |
|  |  |  |  |  |  | diabetic responders (DM-R) (PRI<61%) |  | 6 (7.1%) | OR=1 (calculated) | 0.5-2 | >=61% vs others |  |  |  |
|  |  |  |  |  |  | diabetic low responders (DM-LR) (PRI≥61%) |  | 4 (5.4%) |  |  |  |  |  |  |
| Schafer, 2011{Schafer, 2011 11 /id}21655677GermanyNR | Clopidogrel | VASP | urgent target vessel revascularisation |  | 1 year | >57% |  | 7/40 | OR (calculate)=0.78 | 0.2-3.5 | P=0.71(>57% vs ≤57%)[Fisher’s exact test] | NR | NR | NR |
|  |  |  |  |  |  | </=57% |  | 3/14 |  |  |  |  |  |  |